Tempest Therapeutics (TPST) Other Accumulated Expenses (2011 - 2026)
Tempest Therapeutics (TPST) posted Other Accumulated Expenses of $627000.0 for Q4 2025, down 40.17% sequentially from $1.0 million in Q3 2025, and down 53.03% YoY from $1.3 million in Q4 2024.
Tempest Therapeutics (TPST) Other Accumulated Expenses (2011 - 2026) Analysis & Trends
Tempest Therapeutics has reported Other Accumulated Expenses for 12 years, with the latest figure at $627000.0 in Q4 2025.
- Quarterly Other Accumulated Expenses fell 53.03% year-over-year to $627000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $627000.0 (down 53.03% YoY) and the FY2025 annual result came in at $627000.0, down 53.03% from the prior year.
- Other Accumulated Expenses fell to $627000.0 in Q4 2025 per TPST's latest filing, from $1.0 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $2.0 million in Q2 2024 and troughed at $626000.0 in Q4 2023.
- A 5-year average of $1.1 million and a median of $996500.0 in 2023 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses soared 113.26% in 2024, then sank 53.03% in 2025.
- Over 5 years, Other Accumulated Expenses stood at $748000.0 in 2021, then advanced by 1.07% to $756000.0 in 2022, then slipped by 17.2% to $626000.0 in 2023, then jumped by 113.26% to $1.3 million in 2024, then tumbled by 53.03% to $627000.0 in 2025.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $627000.0, $1.0 million, and $990000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tempest Therapeutics | 4.32 Mn | 3.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 662,000.00 |
| Dec 31, 2025 | 627,000.00 |
| Sep 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | 990,000.00 |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | 1.34 Mn |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 2.03 Mn |
| Mar 31, 2024 | 873,000.00 |
| Dec 31, 2023 | 626,000.00 |
| Sep 30, 2023 | 953,000.00 |
| Jun 30, 2023 | 1.00 Mn |
| Mar 31, 2023 | 1.13 Mn |
| Dec 31, 2022 | 756,000.00 |
| Dec 31, 2021 | 748,000.00 |
| Sep 30, 2019 | 306,000.00 |
| Jun 30, 2019 | 366,000.00 |
| Mar 31, 2019 | 560,000.00 |
| Dec 31, 2018 | 512,000.00 |
| Dec 31, 2017 | 169,000.00 |